Madrigal Pharmaceuticals에 대한 매도 수량은 투자자에게 Madrigal Pharmaceuticals의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Madrigal Pharmaceuticals (NASDAQ:MDGL) 주식, 공매도 수량 보고

Madrigal Pharmaceuticals

Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.

Mid Cap

News

Topics

Movers

Trading Ideas

AAPL

GSAT

MDGL

OMCL

PRCT

이들 7개 중형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 마드리갈 파마슈티컬스(NASDAQ:MDGL)의 주식은 회사가 예상보다 좋은 실적을 발표한 후 51.70% 상승했다.

글로벌스타와 넥스트래커는 지난주 최고 성과를 보여준 7개 중형주 중 일부 (10월 28일-11월 1일)

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals Inc

Stephens &amp; Co. analyst Jim Salera reiterates Domino's Pizza (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NASDAQ">DPZ</a>) with a Equal-Weight and maintains $420 price target.

Price Target

Reiteration

Analyst Ratings

Stephens & Co. Reiterates Equal-Weight on Domino's Pizza, Maintains $420 Price Target

April 3, 2025, Logility's Vision25 will bring together top thought leaders, economists, and AI experts for a virtual event featuring keynote insights and interactive boardroom discussions. During each session, senior supply chain executives—including VPs, SVPs, and C-suite leaders—will explore how AI, geopolitical shifts, and evolving market dynamics are reshaping supply chains.
"The supply chain industry is at a turning point," said Allan Dow, President and CEO, Logility.&nbsp; "AI, economic shifts, and geopolitical tensions are pushing leaders to rethink their strategies. Logility's Vision25 is designed to provide the clarity and direction they need to make informed, forward-thinking decisions."
The series opens with Zack Kass, a futurist and former Head of GTM at OpenAI, who will discuss how artificial intelligence is fundamentally changing business operations and decision-making. Other featured speakers include Mark Blyth, Renowned Political Economist &amp; Professor at Brown University, who will explore how to navigate tariff and trade disruptions and turn them into opportunities, while Maria Villablanca, CEO of Future Insights Network, will share insights on how organizations can build resilience and agility in today's volatile global economy.
Joining these thought leaders, Allan Dow, Logility President and CEO, will highlight how companies can turn supply chain challenges into competitive advantages.
Each week, Logility's Vision25 will focus on a key topic affecting supply chain leaders:
<ul>
<li>March 6, 2025: Explore how organizations can thrive through AI&nbsp; transformations and new leadership approaches required for supply chain development.</li>
<li>March&nbsp; 13, 2025: Address tariffs and trade by analyzing global trade movements and make the most of resulting opportunities.</li>
<li>March 20, 2025: Learn how GenAI can transform supply chain resilience through AI-powered solutions.</li>
<li>March 27, 2025: Discover benchmarks for strategic decision-making in uncertain environments.</li>
<li>April 3, 2025: Logility's Inaugural Reimagine Client Awards will honor innovation and excellence in supply chain transformation.</li>
</ul>
Beyond thought leadership, Logility's Vision25 offers real-world strategies and actionable insights. Attendees will gain exclusive access to Logility's Supply Chain Horizons 2025 Market Report, which highlights emerging trends and key data shaping the industry.

LGTY

Logility's Vision25 to Explore AI, Trade, and Market Shifts Impacting Global Supply Chains

Ukraine and the United States are approaching a deal regarding Ukraine's rare earth minerals, but President Volodymyr Zelensky remains committed to security guarantees. His administration <a target="_blank" href="https://www.benzinga.com/markets/commodities/25/02/43788546/ukraine-officials-stall-trumps-colonial-rare-earths-bid-prefer-mutually-beneficial-deal" rel="noreferrer noopener">delayed the initial push</a> to sign the agreement, asking for military assurances and disputing the financials.
"I don't want something that 10 generations of Ukrainians will have to pay back," Zelensky said at Sunday's press conference, according <a target="_blank" href="https://www.wsj.com/world/ukraines-zelensky-wants-better-terms-on-minerals-deal-demanded-by-trump-7d3a092f" rel="noreferrer noopener">to</a> the Wall Street Journal.
The minerals deal is a part of President Donald Trump's effort to broker a ceasefire on the three-year conflict, as gaining access to Ukraine's resources would reduce reliance on foreign supply chains.
Still, Ukraine is absent from direct negotiations between Washington and Moscow in Saudi Arabia, raising concerns about Kyiv being sidelined from discussions about its own future.
Zelensky warned that Ukraine would not agree to the deal if it did not serve the country's long-term interests. "The deal must be ‘win-win' for Ukraine and the U.S.," he said, pushing back against the Trump administration's argument that American business investments in Ukraine alone would be a security guarantee.
The friction between Kyiv and Washington has risen, with the NY Times <a target="_blank" href="https://www.nytimes.com/2025/02/19/world/europe/ukraine-zelensky-trump-russia-war.html" rel="noreferrer noopener">reporting</a> that Trump called Zelensky a "dictator "for postponing the elections while Zelensky accused Trump of spreading Russian disinformation. Regardless of those tensions, both administrations have proceeded with "constructive "negotiations, per Ukraine's chief of staff, Andrii Yermak.
Despite Trump's interests, it is worth mentioning Ukraine has no internationally recognized rare earth reserves. The country commercially produces some critical minerals, like titanium and gallium, but not at a scale comparable to the enormous sums Trump has suggested.
Ukraine's geological agencies have estimated notable potential deposits, but they are largely undeveloped. Bringing mines into production is a notoriously <a target="_blank" href="https://www.benzinga.com/news/24/07/39870803/us-mine-development-delays-among-worlds-longest-second-only-to-zambia" rel="noreferrer noopener">slow and costly process</a>.
Zelensky also pointed out the disparity between U.S. claims about the cost of its support. While Trump has referenced figures as high as $500 billion, Ukraine's estimates place total U.S. assistance closer to $120 billion, according to the <a target="_blank" href="https://www.ifw-kiel.de/topics/war-against-ukraine/ukraine-support-tracker/" rel="noreferrer noopener">Kiel Institute</a>.
"The question of $500 billion is no longer there," Zelensky said, referring to the initial demand from Washington. "We do not recognize the debt," he added, clarifying that Ukraine would not accept an arrangement that treats U.S. aid as a loan to be repaid through mineral revenues.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/commodities/25/02/43900287/trumps-10-oil-tariff-could-deal-10-billion-annual-blow-to-canada-and-other-foreign-producers-goldman-sachs-warns" target="_blank" rel="noreferrer noopener">Trump's 10% Oil Tariff Could Deal $10 Billion Annual Blow To Canada And Other Foreign Producers, Goldman Sachs Warns</a></li>
</ul>
Image via Shutterstock

Government

Commodities

Politics

Legal

Global

Markets

Zelensky Says Ukraine Won't Trade Minerals For Debt, Seeks 'Win-Win' Deal With US

Goldman Sachs analyst Leah Jordan downgrades Conagra Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAG#NYSE">CAG</a>) from Buy to Neutral and lowers the price target from $33 to $26.

Downgrades

Goldman Sachs Downgrades Conagra Brands to Neutral, Lowers Price Target to $26

WIIM

TRDA

Entrada Therapeutics shares are trading higher after the company announced that the FDA removed the clinical hold on ENTR-601-44 and that it has obtained clearance status.

TD Securities analyst Andrew Charles reiterates Domino's Pizza (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NASDAQ">DPZ</a>) with a Buy and maintains $490 price target.

TD Securities Reiterates Buy on Domino's Pizza, Maintains $490 Price Target

Global life and health reinsurance entity Reinsurance Group of America, Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RGA#NYSE">RGA</a>) shares are <a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener">trading higher in premarket</a> on Monday.
The company has reached an agreement with Equitable Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQH#NYSE">EQH</a>) to reinsure a wide <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43907362/rga-announces-reinsurance-transaction-with-equitable-holdings" rel="noreferrer noopener">range of life insurance products</a>.
Under the terms of the deal, RGA is reinsuring&nbsp;75%&nbsp;of Equitable&#8217;s in-force life insurance liabilities. The block includes approximately&nbsp;$18 billion&nbsp;of general account reserves and&nbsp;$14 billion&nbsp;of separate account reserves.
This deal is set up to allow RGA to invest $1.5 billion in capital at the closing. It is expected to generate returns within RGA&#8217;s projected range, while also providing a notable increase in the company&#8217;s adjusted operating earnings per share.
Furthermore, the agreement expands RGA&#8217;s partnership with Equitable across various sectors, including underwriting, product creation, distribution, and investment management.
&#8220;This partnership is an example of our capacity to provide creative solutions and technical expertise that support both sides of the balance sheet, and it is a prime example of how the execution of our Creation Re strategy can address our clients&#8217; current and future needs,&#8221; said Executive Vice President, Head of the Americas, RGA, Ron Herrmann.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/02/43881721/coca-cola-warns-shortage-of-diverse-talent-could-harm-future-success" rel="noreferrer noopener">Coca-Cola Warns Shortage Of Diverse Talent Could Harm Business</a>
The deal is expected to contribute around $70 million to adjusted operating income before taxes in 2025. This amount is anticipated to increase to between $160 million and $170 million in 2026, eventually stabilizing at around $200 million each year thereafter.
&#8220;Our strong financial position enables us to capitalize on this opportunity with Equitable, and the transaction is expected to meaningfully contribute to RGA&#8217;s earnings per share, with anticipated attractive returns on capital,&#8221; said Executive Vice President, Chief Financial Officer, RGA, Axel André.
RGA intends to fund the transaction with surplus capital and, if necessary, proceeds from debt financing, contingent on market conditions. The transaction is set to close in mid-2025, pending regulatory approval and other customary closing conditions.
The deal is expected to create more than $2 billion in value for Equitable Holdings, encompassing a favorable ceding <a target="_blank" href="https://www.benzinga.com//node/43907593" rel="noreferrer noopener">commission and the release of capital.</a>
Also, Equitable plans to execute $500 million of incremental share repurchases, above the company&#8217;s 60-70% payout ratio target, following the close of the transaction.
Additionally, Equitable announced its intention to <a target="_blank" href="https://www.benzinga.com//node/43907646" rel="noreferrer noopener">increase its ownership stake in AB</a> through a tender offer to purchase up to $1.8 billion of units of AllianceBernstein Holding L.P. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AB#NYSE">AB</a>)
Price Action: RGA shares are trading higher by 3.55% at $196.11 in premarket at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/02/43887830/openai-expands-operator-ai-agent-to-multiple-countries" target="_blank" rel="noreferrer noopener">OpenAI Expands Operator AI Agent To Multiple Countries</a></li>
</ul>
Photo via Shutterstock.

Equities

Asset Sales

General

Equitable Inks Reinsurance Deal With RGA And Plans To Boost Stake In AllianceBernstein: Details

OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, announced the formation of subsidiary OS Drug Conjugates (OSDC). The formation of OSDC coincides with formal strategic options initiatives to create value from the Company's leading-edge, patented silicone dioxide-based, pH sensitive tunable antibody drug conjugates (tADC) &amp; other tunable drug conjugates (tDC) platforms. The Company has initiated discussions with clinical-stage ADC therapeutics companies in the U.S., China and other jurisdictions to form joint ventures (JVs) pairing those companies' clinical-stage assets with certain assets from the tADC and/or tDC platforms and spinning the JVs into standalone public companies. If successful, OS Therapies intends to provide stock dividends of the public JVs to shareholders.
The OST-tADC and OST-tDC technologies are centered around the Company's proprietary next-generation tunable Antibody Drug Conjugate (tADC) and tunable Drug Conjugates (tDC) platforms. These advanced technologies incorporate pH-sensitive silicon-based linkers: SiLinkers&#x2122; to link the targeting antibodies (or antibody fragments) and therapeutic moieties together while coating the entire package with pH sensitive coating. This strategy can release multiple therapeutic agents selectively within the tumor and tumor microenvironment, which have lower pH levels than the rest of the body. This approach aims to maximize the therapeutic effects while minimizing damage to healthy cells.
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.bccresearch.com%2Fmarket-research%2Fpharmaceuticals%2Fantibody-drug-conjugates-markets-report.html%3Fsrsltid%3DAfmBOoqRPnbxc1SPE0lx3HkAmQ-I2X4xd3bWqvtaZu1wAT7gR0oCGUkb&amp;esheet=54212694&amp;newsitemid=20250224482242&amp;lan=en-US&amp;anchor=BCC+Research&amp;index=1&amp;md5=dda6f15610fa07a596439cc152c306cc">BCC Research</a> estimates that the global market for antibody-drug conjugates is estimated to increase from $10.8 billion in 2023 to $47.0 billion by 2029, at a compound annual growth rate (CAGR) of 28.4% from 2024 through 2029.

Dividends

OSTX

OS Therapies Launches Subsidiary to Advance Tunable Antibody Drug Conjugates, Plans Stock Dividends for Shareholders

Goldman Sachs analyst Leah Jordan initiates coverage on Smithfield Foods (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFD#NASDAQ">SFD</a>) with a Buy rating and announces Price Target of $32.

Initiation

Goldman Sachs Initiates Coverage On Smithfield Foods with Buy Rating, Announces Price Target of $32

Barclays analyst David Anderson maintains Tenaris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TS#NYSE">TS</a>) with a Overweight and raises the price target from $48 to $50.

Barclays Maintains Overweight on Tenaris, Raises Price Target to $50

HC Wainwright &amp; Co. analyst Vernon Bernardino reiterates Cardiol Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDL#NASDAQ">CRDL</a>) with a Buy and maintains $9 price target.

CRDL

HC Wainwright & Co. Reiterates Buy on Cardiol Therapeutics, Maintains $9 Price Target

Target Hospitality shares are trading lower after the company announced it lost a key government contract and withdrew its FY25 guidance.

DPZ: -4% &#x7C; <a href="https://www.benzinga.com//node/43908406">Domino's Pizza shares are trading lower after the company reported worse-than-expected Q4 financial results. It also proposed a 15% dividend hike.</a>
&nbsp;
AAPL: -1.5% &#x7C; <a href="https://www.benzinga.com//node/43907712">Apple Commits $500 Billion to US Investment, Focuses on AI and Silicon Innovation</a>
&nbsp;
U: -7% &#x7C; <a href="https://www.benzinga.com//node/43909035">Unity Software shares are trading lower. The company announced a $500 million convertible senior note offering.</a>

Market-Moving News for February 24th

HC Wainwright &amp; Co. analyst Robert Burns reiterates ORIC Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORIC#NASDAQ">ORIC</a>) with a Buy and maintains $21 price target.

ORIC

HC Wainwright & Co. Reiterates Buy on ORIC Pharmaceuticals, Maintains $21 Price Target

GDS Holdings shares are trading lower after Jefferies downgraded the stock from Buy to Hold.

RIVN

Rivian Automotive shares are trading lower after B of A Securities downgraded the stock from Neutral to Underperform and cut its price target from $13 to $10.

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) with a Buy and maintains $48 price target.

PRTA

HC Wainwright & Co. Reiterates Buy on Prothena Corp, Maintains $48 Price Target

On February&nbsp;24, 2025, Leidos Holdings, Inc. (the "Company") announced it has entered into an accelerated share repurchase agreement (the "ASR Agreement") to repurchase $500&nbsp;million of the Company's common stock. These repurchases will be conducted under the Company's ongoing share repurchase authorization.
Pursuant to the ASR Agreement, the Company made an initial payment of $500&nbsp;million to the counterparty financial institution on February&nbsp;20, 2025 and received on the same day initial deliveries of approximately 3&nbsp;million shares of the Company's common stock from the counterparty. The final number of shares to be repurchased by the Company will be based on the volume-weighted average stock price of the Company's common stock during the term of the ASR Agreement, less a discount and subject to adjustments pursuant to the terms and conditions of the ASR Agreement. At settlement, under certain circumstances, the counterparty may be required to deliver additional shares of common stock to the Company, or under certain circumstances, the Company may be required to deliver shares of common stock or to make a cash payment, at its election, to the counterparty. The final settlement under the ASR Agreement is expected during the second quarter of 2025, subject to an earlier completion at the counterparty's option.

Buybacks

LDOS

Leidos Announces $500M Accelerated Share Repurchase Agreement, Buys Back 3M Shares, Final Settlement Expected in Q2 2025

Most people assume that crypto's most popular financial instruments are tokens, but index funds are gaining significant traction. In traditional finance (TradFi), index-based funds have historically outperformed single-asset funds in terms of assets under management (AUM), providing investors with diversified exposure while mitigating risk.
While crypto ETFs, particularly <a href="https://www.sec.gov/newsroom/speeches-statements/gensler-statement-spot-bitcoin-011023">Bitcoin ETFs approved by the Securities and Exchange Commission (SEC) in January 2024</a>, have dominated recent market discussions, index funds offer a broader approach to digital asset investing. Instead of relying on the performance of a single asset, index funds track baskets of assets, creating the diversification that investors have long favored in traditional markets. 
In crypto, this approach holds similar potential. Instead of focusing on a single token like Bitcoin or Ethereum, index funds track multiple high-performing digital assets, offering exposure to the broader market while reducing concentration risk. The Bitwise 10 Crypto Index Fund was one of the first such crypto indexes, launched in 2017, and Fidelity and Bloomberg soon followed with its Bloomberg Galaxy Crypto Index in 2018.
As institutional adoption grows, multi-token index funds that take their unique approach to tracking, benchmarking, and reflecting the overall crypto sector could play a key role in bridging traditional investment strategies with the digital asset space.
<h2 class="wp-block-heading">Indexes spare the hassle &#8211; and risk &#8211; of investing in individual coins</h2>
The abundance of information about a coin &#8211; spread across white papers, discussion boards, social media platforms, and messaging apps &#8211; is difficult to keep up with for one coin, let alone the 1000s of digital assets at any given time. While ETFs save investors the inconvenience of buying, storing, and securing $BTC or other coins with forthcoming ETFs, investors must keep up with this real-time information firehose to manage their portfolios.
When there are many ETFs on the market, investors need to sift through piles of information before deciding which one to ultimately purchase. This is burdensome for most retail investors who simply want some exposure to crypto without getting into the technical details.&nbsp;
From this viewpoint, crypto indexes are a much better option: Investors can defer to the collective growth of a handful of top coins, eliminating the need to perform constant, extensive research on any one coin or ETF.
<h2 class="wp-block-heading">Indexes alleviate users from having to trade short-term </h2>
When investing stocks, short-term trading is often necessary. For instance, if you held shares of Nvidia ($NVDA), you might have felt compelled to buy or sell after the stock dropped following the Deepseek announcement.
In contrast, if you are an investor in the S&amp;P 500, which includes $NVDA, you would not need to respond to any market news. You could buy shares in the S&amp;P 500 and count on the overall growth of the market to withstand any changes to a single stock. Such investors can rest easy, knowing that their investment will always be bullish in the long-term (the S&amp;P boasts an average annual return of over <a href="https://www.investopedia.com/ask/answers/042415/what-average-annual-return-sp-500.asp">10% going back to 1957</a>).
Crypto indexes will be attractive in the same way. Instead of having to regularly take action on a specific token position, investors can simply buy shares in a crypto index and leave them untouched for the long-term. In the parlance of the crypto community, they can "hodl." Such investors can count on the continued growth of crypto to take their shares to new heights over time.
<h2 class="wp-block-heading">Indexes protect investors from the risks associated with FOMO </h2>
The fear of missing out (FOMO) is a real problem in crypto. When investors sit on the sidelines and see peers make money from different financial instruments, they may be prone to jump in and make ill-advised decisions.
FOMO is rampant now with meme coins, which Solana has made easier to launch than ever. A few cycles ago, there was also FOMO for non-fungible tokens and even play-and-earn tokens. All of these instruments are highly volatile. For example, the $SQUID token plummeted 99% in <a href="https://www.bbc.com/news/business-59129466">value in a matter of minutes</a>, while once popular NFT collections, <a href="https://www.theguardian.com/sport/2025/jan/14/almost-10000-images-of-tennis-balls-plunge-up-to-90-in-value-as-australian-open-appears-to-ditch-nfts?utm_source=chatgpt.com">such as those of tennis balls by the Australian Open</a>, were down by 90%.&nbsp;
Indexes can prevent investors from risky FOMO-based decision-making because they already have broad exposure. For example, they would not need to invest in meme coins because most popular indexes include Solana, the preferred blockchain for such assets. Similarly, they would not need to purchase any single NFTs because indexes always have Ethereum, the market leading blockchain for them.&nbsp;
Indexes will likewise give investors exposure to other major trends in the future, all without having to buy into individual assets that are highly risky on their own.
<h2 class="wp-block-heading">Indexing your Crypto Exposure&nbsp;</h2>
As crypto investment vehicles evolve, indexes represent the next logical step in providing retail investors with diversified, low-maintenance exposure to the market. While ETFs solve the challenge of buying and storing individual tokens, they still require investors to stay informed about specific assets. Indexes, on the other hand, simplify the investment process by spreading risk across multiple top-performing cryptocurrencies, much like how traditional stock indexes provide long-term stability.
By mitigating the risks of short-term trading and FOMO-driven decisions, indexes offer a more resilient approach to crypto investing. Whether the market shifts toward new trends or faces periods of volatility, indexes allow investors to participate in crypto's overall growth without the burden of constant research and rebalancing. Just as stock indexes have become a cornerstone of traditional investing, crypto indexes are poised to become a preferred vehicle for long-term, diversified exposure to the digital asset space.&nbsp;
Crypto, in short, operates like a book: The best guide is often the index.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Comments

Madrigal Pharmaceuticals

매도 수량

Madrigal Pharmaceuticals (NASDAQ:MDGL) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌